Nutrition/Obesity

Great @RheumNow Day 2 Daily Recap today talking about trends in SpA therapy, PsA and obesity, gout flares and CV risk, IL-17/23 in PMR/GCA, and as always a healthy dose of 'AI is coming/here'. All the good stuff from #ACR26 with @synovialjoints @AdelaCastro222 @ericdeinmd https://t.co/FSjr2Qn3JC

https://twitter.com/RheumNow/status/2119928161047650786

52 wk data of TOGETHER-PsA: Ixe + Tzp for PsA Ixe+Tzp achieved ACR50 resp & change in body wt thru 52wks; noted superiority by 36wks vs Ixe alone; greater dse control, wt, & metabolic control AEs comparable w/ wk 36 results. Low GI d/c rates @RheumNow #ACR26 Abs2942 https://t.co/MorFe1A4OZ

https://x.com/RHEUMarampa/status/2120535593880793183/photo/1

A2942 TOGETHER-PsA (NCT06588296) Phase 3b, with obese pts Tirzepatide + Ixekizumab combo beat Ixe alone at 52 wks ACR50 43.7% vs 15.7% Weight -20.4% vs -0.6% But 37% of ixe-alone stop Rx vs 20% on combo Target weight and inflammation control in PsA @RheumNow #ACR26 https://t.co/pqfTm2hbwZ

https://x.com/JihaRheum/status/2120534513206096374/photo/1

TOGETHER-PsA by Merola et al may be a practice-changing obesity story. Adding tirzepatide to ixekizumab improved joint outcomes at 52 weeks. Treating inflammation alone may not be enough for some patients with PsA. @rheumnow #ACR2026 #ACRBest Abstract#2942

TOGETHER-PsA at 52 weeks: ACR50 was 43.7% with ixekizumab + tirzepatide vs 15.7% with ixekizumab alone in PsA with overweight/obesity. n=271; open-label RCT. Joint, functional and metabolic outcomes improved. #2942 @Rheumnow #ACR26 #ACRBest https://t.co/zMNyrbAR5m

https://x.com/DrMiniDey/status/2120533255716024760/photo/1

Merola et al. (TOGETHER-PsA): Randomized 271 adults with active PsA and excess weight. Adding tirzepatide to ixekizumab improved joint response, disability and metabolic measures at 52 weeks. Clinical integration is the headline. @rheumnow #ACR2026 Abstract#2942 https://t.co/Yk1ZjCaOTw

https://x.com/Gibson_RheumPAC/status/2120533255418167382/photo/1

Merola et al. (TOGETHER-PsA): Could the next PsA treatment algorithm include an obesity-treatment pathway? TOGETHER-PsA suggests combined inflammatory and metabolic management can improve clinical response. @rheumnow #ACR2026 Abstract#2942 https://t.co/PMu7XZ9SA0

https://x.com/Gibson_RheumPAC/status/2120533003864846483/photo/1

Merola et al. (TOGETHER-PsA): In PsA + obesity, adding tirzepatide to ixekizumab improved ACR50 and several disease-activity measures at week 52. Randomized data; open-label design. @rheumnow #ACR2026 Abstract#2942

Merola et al, TOGETHER-PsA: At 52 weeks, ACR50 was 43.7% with ixekizumab + tirzepatide vs 15.7% with ixekizumab alone. A 28-point difference! Is addressing obesity becoming essential to optimal PsA care? @rheumnow #ACR2026 #ACRBest Abstract#2942

TOGETHER PsA at 52 weeks. Topline: ACR50 43.7% with ixekizumab plus tirzepatide vs 15.7% with ixekizumab alone; ACR50 with ≥10% weight loss 39.2% vs 1.7%. Key finding: the difference in ACR50 increased between week 36 and week 52. @rheumnow #ACR26 Abstract#2942 https://t.co/F77NgUoDXD

Also highly anticipated on last day of #ACR26: TOGETHER-PsA 52w data ixekizumab + tirzepatide vs ixekizumab the difference just gets starker Is it disease modifying? Does it matter? #ACR26 will be remembered as the meeting GLP-1 RA arrived in rheum ABST2942 #ACR26 @RheumNow https://t.co/2xFDN39tEu

https://x.com/drdavidliew/status/2120502578731708920/photo/1

Article

Falls Hide in Plain Sight in Rheumatic Disease

Jiha Lee, MD Nov 11, 2026

Katherine Wysham, MD, in the session “Rheumatology for Every Age” at ACR 2026 noted that falls are common in people with arthritis and underreported. A fall tends to start a cycle: lost confidence, less going out, reduced social participation, deconditioning, and then more falls and fractures.

Weight loss & getting fit isn't just about structural changes. In RA patients, it's possibly dialling back inflammaging with real impacts for muscle-immune crosstalk. That's not just feel good, that was disease activity & function. Fascinating plenary ABST2803 #ACR26 @RheumNow https://t.co/OfXY0gwgt5

https://x.com/drdavidliew/status/2120471860286816444/photo/1

Weight Loss and Arthritis: A focus on patient-reported outcomes Obesity is associated with poorer physical function and treatment response in rheumatoid arthritis (RA). The ACR guideline on exercise, rehabilitation and diet supports discussing healthy body weight as part of https://t.co/GynYYRqC4T

ACR 2026 guidelines for management of OA 1. Self management programs: educate pts on the disease and involve them in their care. 2. PT/OT-Key! 3. Mobility aids if limited walking. 4. Exercise! all of them recommended. 5. Wt loss if hip/knee OA and overwt or obese 6. Topical https://t.co/JnbNaZ3CSw

Tirzepatide: A Vascular Advantage in RA? #ACR26 Abstract #1424: In 7,944 matched patients with RA and T2DM, tirzepatide was associated with fewer thromboembolic/CV events vs GLP-1 RAs (HR 0.84; 95% CI 0.73–0.98). Promising, but unequal follow-up warrants caution. @RheumNow https://t.co/rT7vTaWY0G

https://x.com/Mota_licia_reum/status/2120254300236423288/photo/1

ACR 2026 – Day 1 Report ACR Convergence was off to a big start with the year in review, posters and plenary sessions. Here are a few of our favorite presentations from today's Plenary I session at ACR Convergence. 2/5 plenary abstracts focused on weight loss, one on artificial https://t.co/d1u0nElhov

Accdg to this study, milk composition - macronutrients - of pts with SARDs was comparable to controls. Key takeaway? Counsel mothers w/ SARDs and advocate for breastfeeding. @RheumNow #ACR26 Abs2458 https://t.co/2JclXSYRJi

https://x.com/RHEUMarampa/status/2120235383103664231/photo/1

Ixekizumab + tirzepatide vs. Ixekizumab alone in PsA TOGETHER-PsA Trial Primary outcome: ACR50 + 10% weight loss... So Ixe alone barely met this - setup for failure w/ this outcome Raw ACR20/50/70 more interesting - combo did better @RheumNow #ACR26 Abst2297 https://t.co/fBOcq4UIjy

https://x.com/Dr_Brian_MD/status/2120229370384003582/photo/1

Jamshaid & Gomaa (Tirzepatide vs semaglutide cohort): tirzepatide was associated with lower 1-year and 3-year risks of treatment-defined flare proxies compared with semaglutide. @rheumnow #ACR2026 Abstract#2641

Jamshaid & Gomaa (Tirzepatide vs semaglutide cohort): A large real-world comparison found less steroid use with tirzepatide than semaglutide at 3 years: 27.2% vs 37.5%.@rheumnow #ACR2026 Abstract#2641

Jamshaid & Gomaa (Tirzepatide vs semaglutide cohort): Tirzepatide vs semaglutide in inflammatory arthritis: steroid use at 1 year was 19.1% vs 22.5% in matched cohorts. @rheumnow #ACR2026 Abstract#2641

Weber et al. (TOGETHER PsO&PsA): 30% lower predicted 10-year CVD risk vs pts IXE mono. suggest that targeting both inflammatory and metabolic pathways may improve CV benefit and potentially reduce long-term CV burden in this high-risk population. @rheumnow #ACR2026 Abstract#2299

TOGETHER-PsA (n=271): week 36, 31.7% on ixekizumab + tirzepatide vs 0.8% on ixekizumab alone achieved BOTH ACR50 and >=10% weight loss. Adding tirzepatide to ixe improved PsA disease control as early as WK4 alongside weight loss in overweight or obese pts. #2297 #ACR26 @Rheumnow

Weber et al. (TOGETHER cardiometabolic analysis): ixekizumab + tirzepatide was associated with about 30% lower predicted 10-year CV risk vs ixekizumab alone at week 36. @rheumnow #ACR2026 Abstract#2299 https://t.co/NmulNKUwLL

https://x.com/Gibson_RheumPAC/status/2120207359179948201/photo/1

Topics

Nutrition/Obesity

Falls Hide in Plain Sight in Rheumatic Disease

Daily Download

TNR Slides: Obesity & Inflammation Webinar

Podcasts

Topic Videos

Do you get our email newsletter?